Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons

Expert Opin Pharmacother. 2023 Sep-Dec;24(15):1657-1660. doi: 10.1080/14656566.2023.2237414. Epub 2023 Jul 18.
No abstract available

Keywords: Tirzepatide; incretins; legacy effect; pharmacotherapy; type 2 diabetes.

Publication types

  • Editorial

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents / adverse effects

Substances

  • tirzepatide
  • Gastric Inhibitory Polypeptide
  • Hypoglycemic Agents
  • Glucagon-Like Peptide-1 Receptor